Who are Vitranu's investors?

Vitranu's investors include JobsOhio Ventures, JumpStart Equity.

How much funding has Vitranu raised?

Vitranu has disclosed $1.5M raised across 1 round.

Where is Vitranu headquartered?

Vitranu is headquartered in Columbus, US.

Vitranu

Columbus, US · Founded 2020 · Delaware corporation · 2 known investors

Find your way into Vitranu

20 people in our graph share verified history with the Vitranu team — schools, employers, funds. One of them is your warm intro.

Brian Levyunlockedknows Matthew Ohr · together at Vitranu (overlapped)

×11knows the team · via The Ohio State University Wexner Medical Center

Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

John BlackCEO

Katelyn Swindle-ReillyChief Technology Officer

Matthew Ohr Chief Medical OfficerMatthew Ohr previously served as Interim Chair and Retina Division Director at The Ohio State University Department of Ophthalmology. He is Chief Medical Officer of Vitranu, which develops biomaterial and biologic technologies for ophthalmic applications.

Joe Seiwert IIIChief Product Development Officer

Wayne EmbreeNamed on SEC filing

Brad BeaseckerNamed on SEC filing

Gary CharbonneauNamed on SEC filing

Robin SearsChairman Of The Board Of DirectorsDirector at Myoptechs

Brian PriceDirector CMC

Gordon BethwaiteStrategic Sanint Consultant

Investors · 2

JobsOhio Ventureslisted by JobsOhio VenturesColumbus

How we know: JobsOhio Ventures's portfolio page · Not right? Tell us

JumpStart Equitylisted by JumpStart EquityCleveland

Reported raises · per SEC filings

Form D private placements

$1.5M disclosed across 1 round · 2021

▶$1.5MraisedOct 2021 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Wayne EmbreeDirector
Gordon BethwaiteExecutive Officer, Director
Brad BeaseckerExecutive Officer
Gary CharbonneauDirector
Robin SearsDirector

Offering amount: $3M
Amount sold: $1.5M
First sale: Oct 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Veratx4 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.

Ois4 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

Arvinas Holding Co. LLC4 shared keywordsArvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

Companies competing with Vitranu for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Vitranu do?: Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.
Who are Vitranu's investors?: Vitranu's investors include JobsOhio Ventures, JumpStart Equity.
How much funding has Vitranu raised?: Vitranu has disclosed $1.5M raised across 1 round.
Where is Vitranu headquartered?: Vitranu is headquartered in Columbus, US.